loading
前日終値:
$3.12
開ける:
$3.15
24時間の取引高:
48,213
Relative Volume:
1.15
時価総額:
$4.38M
収益:
-
当期純損益:
$-11.28M
株価収益率:
-1.0797
EPS:
-3.01
ネットキャッシュフロー:
$-9.78M
1週間 パフォーマンス:
-5.80%
1か月 パフォーマンス:
-38.10%
6か月 パフォーマンス:
-24.77%
1年 パフォーマンス:
-72.58%
1日の値動き範囲:
Value
$3.05
$3.58
1週間の範囲:
Value
$3.05
$3.70
52週間の値動き範囲:
Value
$2.118
$14.67

Ensysce Biosciences Inc Stock (ENSC) Company Profile

Name
名前
Ensysce Biosciences Inc
Name
セクター
Healthcare (1166)
Name
電話
(858) 263-4196
Name
住所
7946 IVANHOE AVENUE, LA JOLLA
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
ENSC's Discussions on Twitter

ENSC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ENSC
Ensysce Biosciences Inc
3.25 4.38M 0 -11.28M -9.78M -3.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Ensysce Biosciences Inc (ENSC) 最新ニュース

pulisher
Mar 27, 2025

(ENSC) On The My Stocks Page - Stock Traders Daily

Mar 27, 2025
pulisher
Mar 20, 2025

Ensysce Biosciences Advances in Opioid Innovation - TipRanks

Mar 20, 2025
pulisher
Mar 19, 2025

Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga

Mar 19, 2025
pulisher
Mar 18, 2025

Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025 - StockTitan

Mar 18, 2025
pulisher
Mar 17, 2025

How the (ENSC) price action is used to our Advantage - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 14, 2025

Zacks Small Cap Issues Negative Forecast for ENSC Earnings - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - EIN News

Mar 13, 2025
pulisher
Mar 12, 2025

When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St

Mar 12, 2025
pulisher
Mar 12, 2025

Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 12, 2025
pulisher
Mar 10, 2025

Ensysce Biosciences, Inc. SEC 10-K Report - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status - StockTitan

Mar 10, 2025
pulisher
Mar 06, 2025

(ENSC) Long Term Investment Analysis - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 05, 2025

Ensysce Biosciences to Present Pain Management Innovations at ROTH Conference - StockTitan

Mar 05, 2025
pulisher
Mar 03, 2025

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton Unive - GuruFocus.com

Mar 03, 2025
pulisher
Feb 27, 2025

Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 20, 2025

Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 20, 2025

Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 17, 2025

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire

Feb 17, 2025
pulisher
Feb 13, 2025

How To Trade (ENSC) - Stock Traders Daily

Feb 13, 2025
pulisher
Feb 05, 2025

Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan

Feb 05, 2025
pulisher
Feb 04, 2025

When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)? - Yahoo Finance

Feb 04, 2025
pulisher
Jan 27, 2025

Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 26, 2025

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 25, 2025

Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 24, 2025

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 22, 2025

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - NEWSnet

Jan 22, 2025
pulisher
Jan 22, 2025

Ensysce reports overdose protection in drug trial - Investing.com

Jan 22, 2025
pulisher
Jan 22, 2025

Ensysce's PF614-MPAR Shows Breakthrough Overdose Protection in Phase 1b Opioid Trial - StockTitan

Jan 22, 2025
pulisher
Jan 09, 2025

Biotech Steals The Show Following $14 Million Grant Announcement - MSN

Jan 09, 2025
pulisher
Jan 08, 2025

Ensysce's Breakthrough Pain Drug Gets FDA Special Status; Secures $23.7M Funding Boost - StockTitan

Jan 08, 2025
pulisher
Jan 02, 2025

Ensysce Biosciences (NASDAQ:ENSC) Shares Down 5.6% – Should You Sell? - Defense World

Jan 02, 2025
pulisher
Dec 23, 2024

Ensysce Biosciences Regains Full Compliance with Nasdaq - Financial Content

Dec 23, 2024
pulisher
Dec 10, 2024

Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection Drug Development - StockTitan

Dec 10, 2024
pulisher
Dec 08, 2024

983,518 Shares in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Bought by Anson Funds Management LP - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

ENSC Stock Touches 52-Week High at $7.24 Amid Market Volatility - Investing.com Nigeria

Dec 07, 2024
pulisher
Dec 07, 2024

Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 - Marketscreener.com

Dec 07, 2024
pulisher
Dec 06, 2024

Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study - Marketscreener.com

Dec 06, 2024
pulisher
Dec 06, 2024

Revolutionizing Pain Relief: The next generation of opioids | Interview with Ensysce Biosciences CEO - Marketscreener.com

Dec 06, 2024
pulisher
Dec 06, 2024

Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol - Marketscreener.com

Dec 06, 2024
pulisher
Dec 06, 2024

Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com

Dec 06, 2024

Ensysce Biosciences Inc (ENSC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):